최소침습 녹내장 수술 장치 시장 : 장치 유형, 수술 부위, 적응증, 수술 접근, 수술 방법, 임플란트 재료, 장치 분류, 지불 방법, 환자 유형, 최종 사용자, 유통 채널별 예측(2026-2032년)

The Minimally Invasive Glaucoma Surgery Devices Market was valued at USD 601.69 million in 2024 and is projected to grow to USD 635.51 million in 2025, with a CAGR of 5.80%, reaching USD 944.80 million by 2032.

A clear and concise overview of minimally invasive glaucoma surgery devices, their clinical rationale, adoption drivers, and implications for clinical practice

Minimally invasive glaucoma surgery (MIGS) devices have reshaped therapeutic strategies for glaucoma management by offering safer, less invasive alternatives to traditional filtration surgeries. These technologies prioritize rapid recovery, reduced perioperative risk, and suitability for earlier intervention in the disease continuum, thereby aligning with clinician preferences for procedures that balance efficacy and safety. Adoption has been driven by an expanded evidence base, iterative device design improvements, and shifting clinical guidelines that increasingly recognize the role of MIGS for patients undergoing cataract surgery as well as for select standalone indications.

As a consequence, stakeholders across clinical, commercial, and regulatory domains must reassess investment priorities, training programs, and supply-chain design to respond to wider MIGS adoption. Surgeons are refining patient selection criteria and surgical workflows, while health systems evaluate resource allocation across ambulatory surgery centers and specialty clinics. Together, these dynamics underscore the need for a holistic market view that connects device innovation, procedural strategy, and operational readiness to realize the full value proposition of MIGS technology.

How technological refinement, evolving clinical evidence, and health system priorities are reshaping the minimally invasive glaucoma surgery market and care delivery pathways

The MIGS landscape is undergoing transformative shifts catalyzed by technological refinement, expanded clinical evidence, and systemic pressures that favor outpatient and value-based care. Iterations in implant geometry and delivery systems have improved ease of implantation and lowered complication rates, which in turn reinforce surgeon confidence and broaden candidate profiles. In parallel, procedural innovation-particularly the normalization of combined cataract and glaucoma procedures-has created new pathways for earlier intervention while blurring traditional boundaries between subspecialty and general ophthalmic practice.

Concurrently, regulatory and payer frameworks are evolving to better account for long-term outcomes, quality-of-life metrics, and the cost offsets associated with reduced postoperative morbidity. This regulatory maturation is accompanied by increased attention to scalability through manufacturing standardization and supply-chain resilience. As a result, manufacturers are prioritizing modular platform approaches and interoperability with surgical visualization tools, while clinical training programs emphasize reproducible techniques and outcomes monitoring. Collectively, these factors are converging to reshape competitive positioning and to expand the clinical utility of MIGS across diverse care settings.

Evaluating how the cumulative effect of 2025 tariff measures reshapes sourcing, manufacturing footprints, and procurement strategies for minimally invasive glaucoma device makers

The introduction of new tariff policies and trade measures in 2025 has introduced a material shock to the global supply chains that underpin medical-device production, with implications for components, raw materials, and subassembly sourcing. For MIGS devices, which rely on specialized metals such as nitinol and titanium as well as a range of polymeric materials, cumulative tariff effects create upward pressure on input costs and compel manufacturers to reassess sourcing strategies. As firms respond, many are accelerating supplier diversification, nearshoring of critical production steps, and vertical integration for high-value components to mitigate exposure to import taxes and cross-border logistical volatility.

These dynamics are not limited to procurement. Regulatory documentation and quality systems must adapt when manufacturing footprints change, potentially elongating time-to-market for iterations and new product introductions. In the clinical setting, cost pressures can translate into more rigorous evaluations of device selection, influencing hospital formulary decisions and contracting dynamics with ambulatory surgery centers and specialty hospitals. Consequently, organizations that proactively optimize procurement, engage in scenario-based pricing strategies, and invest in localized manufacturing capability are better positioned to preserve margins and sustain clinical adoption amid tariff-driven uncertainty.

A comprehensive segmentation-driven analysis connecting device typology, clinical indications, surgical approaches, materials, end users, and distribution channels to strategic priorities

A granular segmentation lens reveals nuanced opportunities and constraints that cut across product design, clinical positioning, and commercial strategy. By device type, the field encompasses Schlemm's canal scaffolds and expanders, subconjunctival microshunts, suprachoroidal microshunts, and trabecular bypass stents, the latter of which is differentiated between multi-stent systems and single-stent systems; each modality carries distinct efficacy profiles, implantation techniques, and evidence-generation pathways that influence adoption curves. When viewed by indication, clinical utility varies across angle-closure glaucoma, congenital glaucoma, primary open-angle glaucoma, and secondary glaucoma, requiring tailored clinical trials and labeling strategies to validate safety and effectiveness for specific patient cohorts.

Surgical approach segmentation separates ab externo from ab interno procedures, which has direct implications for required instrumentation, surgeon training, and intraoperative workflow. Procedure type further differentiates combined with cataract surgery interventions from standalone procedures, influencing perioperative planning and reimbursement coding. Material selection-metals versus polymers with metals subdivided into nitinol and titanium and polymers into gelatin/collagen, polyethersulfone, polyimide, and silicone-affects biocompatibility, durability, and manufacturing complexity, and therefore informs both regulatory strategy and supply-chain risk assessments. End-user segmentation across ambulatory surgery centers, ophthalmic clinics, and specialty eye hospitals highlights variance in purchasing behavior, volume thresholds, and clinical throughput, while distribution channel distinctions between offline and online influence pricing transparency and logistics. Integrated consideration of these dimensions enables companies to align product pipelines, clinical evidence generation, and commercialization tactics to the realities of adoption across different clinical and commercial contexts.

Regional dynamics and market-access considerations across Americas, Europe Middle East & Africa, and Asia-Pacific that inform regulatory, commercial, and operational strategies

Regional dynamics continue to shape product strategy, regulatory pathways, and commercial traction across the globe. In the Americas, regulatory rigor and established reimbursement frameworks enable earlier commercialization for devices supported by robust clinical evidence, and the prominence of ambulatory surgery centers creates an operational environment conducive to MIGS uptake. This region also tends to favor innovation that demonstrably reduces postoperative burden, making surgical ease-of-use and reproducible outcomes central to commercial success. Transitioning eastward, Europe, Middle East & Africa presents a mosaic of regulatory regimes, payer structures, and procurement practices; while some markets adopt harmonized regulatory standards that facilitate cross-border entry, others require localized clinical data and tailored costing models, which means commercial strategy must be regionally calibrated.

In Asia-Pacific, the market environment is characterized by a mix of advanced adoption in economies with high ophthalmic care capacity and rapid growth potential in emerging markets where expanding surgical infrastructure is enabling increased procedure volumes. Local manufacturing capabilities, government-driven healthcare investments, and distinct clinical practice patterns influence device selection and pricing dynamics. Across all regions, strategic partnerships with local distributors, investment in surgeon training, and sensitivity to procurement timelines are critical enablers for sustained market penetration and scale.

How competitive positioning, clinical evidence strategies, and strategic partnerships are defining leadership and differentiation among minimally invasive glaucoma device manufacturers

Competitive dynamics in the MIGS arena are shaped by the interplay of established medical-device manufacturers, ophthalmic-focused firms, and emergent startups pursuing differentiated technical approaches. Leading organizations emphasize robust clinical programs and post-market surveillance to substantiate comparative effectiveness and long-term safety, while smaller innovators leverage targeted niches-such as novel implant geometries, soft polymer materials, or delivery system ergonomics-to gain initial clinical traction. Strategic activity frequently centers on partnerships that accelerate distribution, co-development arrangements that consolidate surgical platforms, and selective acquisitions that expand portfolios to cover complementary procedural approaches.

Intellectual property protection, regulatory pathway expertise, and the ability to generate reproducible real-world evidence are recurring determinants of competitive advantage. Companies that invest in surgeon education, digital support tools for intraoperative guidance, and comprehensive outcomes registries not only shorten adoption cycles but also create defensible differentiation in a market where incremental product improvements can materially influence selection criteria. Going forward, the firms that most effectively integrate clinical data, surgeon workflows, and supply-chain resilience will define the leadership tier within the MIGS ecosystem.

Practical and prioritized strategic actions for manufacturers, health systems, and distributors to strengthen adoption, evidence generation, and supply-chain resilience in MIGS

Leaders in the MIGS ecosystem should pursue a set of actionable priorities that align clinical value with operational resilience. First, prioritize clinical evidence generation that addresses comparative effectiveness versus alternative surgical options and substantiates benefits in combined and standalone indications; this will strengthen discussions with payers and hospital formulary committees. Second, optimize supply chains through supplier diversification, consideration of localized manufacturing for high-risk components, and inventory strategies that reduce exposure to trade disruptions and tariff variability.

Third, invest in surgeon training and proctoring programs that shorten the learning curve for ab interno and ab externo approaches while demonstrating consistent outcomes across practice settings. Fourth, adopt pricing and contracting models that recognize the heterogeneity of end users, from ambulatory surgery centers to specialty hospitals, and enable flexible commercial engagement across offline and online distribution channels. Finally, cultivate partnerships with digital health vendors and imaging-platform providers to enhance intraoperative visualization and outcomes tracking, thereby creating integrated solutions that offer demonstrable clinical and economic value to payers and providers alike.

A transparent and evidence-based research methodology integrating primary expert interviews, systematic clinical review, and triangulation to validate strategic insights

This analysis synthesizes primary and secondary methodologies to ensure a balanced, evidence-informed perspective. Primary research included structured interviews with ophthalmic surgeons, hospital procurement leaders, and device development professionals to capture real-world insights into procedural preferences, device selection criteria, and supply-chain considerations. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, and publicly available procedural guidelines to triangulate efficacy, safety, and pathway requirements. Together, these approaches informed a layered understanding of both clinical and commercial dynamics.

To validate findings, cross-referencing of clinical outcomes with expert input and regulatory precedent was undertaken, and sensitivity checks were applied to qualitative inferences to reduce bias. Where appropriate, gaps in published evidence were mitigated by targeted follow-up interviews and by examining analogous device categories for transferable lessons. While every effort was made to ensure comprehensiveness, readers should recognize the evolving nature of clinical data and the potential for regulatory changes to alter the landscape; therefore, periodic reassessment is advisable to maintain strategic relevance.

A concise synthesis of strategic takeaways highlighting how evidence, commercialization, and operational resilience shape long-term success in MIGS

Minimally invasive glaucoma surgery devices represent a maturing but still rapidly evolving segment of ophthalmic care where incremental innovation, clinical evidence, and operational readiness converge to determine adoption trajectories. The interplay between device typology, surgical approach, material selection, and end-user settings creates a complex landscape that rewards specificity in clinical development and nimbleness in commercial execution. As supply-chain pressures and policy dynamics evolve, the capacity to adapt procurement, manufacturing, and training programs will increasingly separate resilient players from those exposed to disruption.

In sum, stakeholders that align rigorous evidence generation with targeted commercialization, proactive supply-chain risk management, and meaningful engagement with surgical communities will be best positioned to translate technological promise into durable clinical and commercial outcomes. Continuously updated intelligence and scenario planning are essential to anticipate shifts in regulation, reimbursement, and geopolitical influences that could affect market access and competitive advantage.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2024
• 3.5. FPNV Positioning Matrix, 2024
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimally Invasive Glaucoma Surgery Devices Market, by Device Type

• 8.1. Ablation Tools
• 8.2. Catheter
• 8.3. Lumen-Based Shunts
  • 8.3.1. Fixed-Lumen
  • 8.3.2. Flow-Controlled
• 8.4. Scaffold/Expander
• 8.5. Stents

9. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Site

• 9.1. Ciliary Body
• 9.2. Schlemm's Canal
• 9.3. Subconjunctival Space
• 9.4. Suprachoroidal Space
• 9.5. Trabecular Meshwork

10. Minimally Invasive Glaucoma Surgery Devices Market, by Indication

• 10.1. Angle-Closure Glaucoma
• 10.2. Congenital Glaucoma
• 10.3. Primary Open Angle Glaucoma
• 10.4. Secondary Glaucoma

11. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Approach

• 11.1. Ab Externo
• 11.2. Ab Interno

12. Minimally Invasive Glaucoma Surgery Devices Market, by Procedure Type

• 12.1. Combined With Cataract Surgery
• 12.2. Standalone Procedure

13. Minimally Invasive Glaucoma Surgery Devices Market, by Implant Material

• 13.1. Metals
  • 13.1.1. Nitinol
  • 13.1.2. Titanium
• 13.2. Polymers
  • 13.2.1. Gelatin
  • 13.2.2. Polyethersulfone
  • 13.2.3. Polyimide
  • 13.2.4. Silicone

14. Minimally Invasive Glaucoma Surgery Devices Market, by Device Class

• 14.1. Implantable
• 14.2. Non-implantable

15. Minimally Invasive Glaucoma Surgery Devices Market, by Payment Method

• 15.1. Reimbursement-Based
• 15.2. Self-Pay

16. Minimally Invasive Glaucoma Surgery Devices Market, by Patient Type

• 16.1. Pediatric
• 16.2. Adult

17. Minimally Invasive Glaucoma Surgery Devices Market, by Usability

• 17.1. Reusable
• 17.2. Disposable

18. Minimally Invasive Glaucoma Surgery Devices Market, by End User

• 18.1. Ambulatory Surgery Centers
• 18.2. Ophthalmic Clinics
• 18.3. Specialty Eye Hospitals

19. Minimally Invasive Glaucoma Surgery Devices Market, by Distribution Channel

• 19.1. Offline
• 19.2. Online

20. Minimally Invasive Glaucoma Surgery Devices Market, by Region

• 20.1. Americas
  • 20.1.1. North America
  • 20.1.2. Latin America
• 20.2. Europe, Middle East & Africa
  • 20.2.1. Europe
  • 20.2.2. Middle East
  • 20.2.3. Africa
• 20.3. Asia-Pacific

21. Minimally Invasive Glaucoma Surgery Devices Market, by Group

• 21.1. ASEAN
• 21.2. GCC
• 21.3. European Union
• 21.4. BRICS
• 21.5. G7
• 21.6. NATO

22. Minimally Invasive Glaucoma Surgery Devices Market, by Country

• 22.1. United States
• 22.2. Canada
• 22.3. Mexico
• 22.4. Brazil
• 22.5. United Kingdom
• 22.6. Germany
• 22.7. France
• 22.8. Russia
• 22.9. Italy
• 22.10. Spain
• 22.11. China
• 22.12. India
• 22.13. Japan
• 22.14. Australia
• 22.15. South Korea

23. United States Minimally Invasive Glaucoma Surgery Devices Market

24. China Minimally Invasive Glaucoma Surgery Devices Market

25. Competitive Landscape

• 25.1. Market Concentration Analysis, 2024
  • 25.1.1. Concentration Ratio (CR)
  • 25.1.2. Herfindahl Hirschman Index (HHI)
• 25.2. Recent Developments & Impact Analysis, 2024
• 25.3. Product Portfolio Analysis, 2024
• 25.4. Benchmarking Analysis, 2024
• 25.5. AbbVie Inc.
• 25.6. Alcon Vision LLC
• 25.7. Bausch + Lomb Corp.
• 25.8. BVI Medical, Inc.
• 25.9. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
• 25.10. Glaukos Corporation
• 25.11. Haag-Streit Group by Metall Zug AG
• 25.12. Iridex Corporation
• 25.13. iSTAR Medical
• 25.14. Johnson & Johnson Services, Inc.
• 25.15. Lumibird Medical
• 25.16. New World Medical, Inc.
• 25.17. Nova Eye Medical Limited
• 25.18. Oertli Instrumente AG
• 25.19. Santen Pharmaceutical Co., Ltd.